
Opinion|Videos|December 21, 2023
NSCLC: Dato-DXd Combination Therapy
Author(s)Anne S. Tsao, MD, Edward B. Garon, MD, MS
Expert perspectives on clinical trials investigating doublet and triplet therapy with datopotamab deruxtecan in patients with non–small cell lung cancer.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















